Spindle Pole Coupling Failure as a Progressive Driver of Differentiation Suppression in Cancer Initiation

Background: Current cancer initiation models, including multi-hit genomic models and chromosomal instability (CIN) frameworks, do not account for a mechanistically distinct upstream event: progressive protein coupling failure at the spindle pole during mitosis. We propose a novel hypothesis in which coupling failure among spindle pole-resident proteins actively suppresses differentiation commitment in daughter cells across successive cell generations, providing a unifying upstream mechanism for the dedifferentiation that precedes and enables malignant transformation. Hypothesis: A single seed event — a mutation, overexpression, or aberrant post-translational modification in one spindle pole-resident protein — is sufficient to disrupt coupling fidelity at the pole and initiate differentiation suppression. Each additional pole-resident protein that subsequently fails to couple correctly amplifies this effect in a compounding manner, such that the number of miscoupled proteins is directly proportional to the severity of differentiation loss in resulting daughter cells. This is a gain-of-aberrant-function mechanism at the protein interaction level, not a loss-of-function mutational event, and is not captured by existing cancer initiation models. Evidence: A formal enrichment analysis using Fisher's exact test across the full COSMIC Cancer Gene Census (719 genes) against the mitotic pericentriolar proteome (392 proteins; 260 unique gene mappings) reveals genome-wide significant enrichment of cancer genes at spindle poles (p = 1.32 x 10^-9, odds ratio 3.89, 3.4-fold enrichment), with 32 cancer genes observed at spindle poles versus 9.3 expected by chance. Conclusions: The spindle pole coupling failure model contains existing models as downstream consequences while adding a distinct upstream initiating mechanism. It generates testable experimental predictions and identifies a novel therapeutic target class: allosteric inhibitors of cancer-specific coupling interfaces at the spindle pole.